Abzena PLC (LON:ABZA) has successfully manufactured a potential new cancer drug that incorporates the company’s Composite Human Antibody platform.
The ‘Abzena Inside’ technology was deployed to enhance Clevegen, a pre-clinical treatment being developed by Faron Pharmaceuticals Ltd (LON:FARN).
READ: Abzena signs manufacturing and bioconjugational agreement with Telix
Abzena said the manufacture of the new product took place at its site in San Diego, but used the bioanalytics and bioassay expertise of its Cambridge operation.
"We are pleased to have enabled the progression of an Abzena Inside antibody towards clinical development through this partnership,” said Jim Mills, head of technical operations.
“It really demonstrates the depth of our integrated services and technologies, showing how our sites work together to provide the support that our partners require to move their products forward from molecule design into clinical trials."
The company has a twin strategy: it provides support services for the bio-pharma industry and it grafts its technologies into drugs hoping to enhance efficacy.
The latter is the company’s ‘Abzena Inside’ strategy, which mirrors the approach taken by chipmaker Intel, which provides the processors that power millions of PCs and laptops worldwide.